ABSTRACT
In the current study, phage-exposed mimotopes as targets against tegumentary leishmaniasis (TL) were selected by means of bio-panning cycles employing sera of TL patients and healthy subjects, besides the immune stimulation of peripheral blood mononuclear cells (PBMCs) collected from untreated and treated TL patients and healthy subjects. The clones were evaluated regarding their specific interferon-γ (IFN-γ) and interleukin-4 (IL-4) production in the in vitro cultures, and selectivity and specificity values were calculated, and those presenting the best results were selected for the in vivo experiments. Two clones, namely A4 and A8, were identified and used in immunization protocols from BALB/c mice to protect against Leishmania amazonensis infection. Results showed a polarized Th1 response generated after vaccination, being based on significantly higher levels of IFN-γ, IL-2, IL-12, tumour necrosis factor-α (TNF-α) and granulocyte-macrophage colony-stimulating factor (GM-CSF); which were associated with lower production of specific IL-4, IL-10 and immunoglobulin G1 (IgG1) antibodies. Vaccinated mice presented significant reductions in the parasite load in the infected tissue and distinct organs, when compared with controls. In conclusion, we presented a strategy to identify new mimotopes able to induce Th1 response in PBMCs from TL patients and healthy subjects, and that were successfully used to protect against L. amazonensis infection.
Subject(s)
Leishmania mexicana/immunology , Leishmaniasis Vaccines/immunology , Leishmaniasis, Cutaneous/immunology , Leukocytes, Mononuclear/immunology , Adult , Animals , Bacteriophages/immunology , Female , High-Throughput Screening Assays , Humans , Male , Mice , Mice, Inbred BALB C , Middle Aged , T-Lymphocytes/immunology , Young AdultABSTRACT
Serological tests are important tools for the diagnosis of Leishmania infection. However, they are not effective markers to diagnose asymptomatic cases of visceral leishmaniasis (VL) and patients developing tegumentary leishmaniasis (TL), since antileishmanial antibodies can be encountered in low levels resulting in false-negative results in the serological trials. In this context, antigens able to be recognized by antibodies in sera from both VL and TL patients will be desirable to be employed in a more sensitivity and specific diagnosis of disease. In the present study, a conserved Leishmania protein, small myristoylated protein-3 (SMP-3), which was showed to be conserved in different Leishmania species and an effective vaccine candidate against Leishmania infantum infection in a murine model, was cloned and the recombinant protein was evaluated as a serological marker for the diagnosis of human TL and canine VL. In addition, a linear B cell-specific epitope (MQKDEESGEFKCEL) was identified, synthetized and also investigated as a serological marker. As antigen controls, rA2 protein and antigenic Leishmania extracts (SLA) were used. Results showed that ELISA-rSMP-3 and ELISA-Peptide presented sensitivity and specificity values higher than 90% in both diseases in humans and canids, having identified all asymptomatic cases and did not present cross-reaction with cross-reactivity diseases in both mammalian hosts. On the other hand, sensitivity and specificity values were worst when rA2 or SLA were used as antigens in humans and dogs. In conclusion, results showed the efficacy and Leishmania SMP-3 protein, employed as a recombinant antigen or a B cell epitope, for the improvement of the serodiagnosis of human TL and canine VL. This candidate can be tested in other diagnostic platforms, such as rapid immunochromatographic dipstick tests, aiming its use in epidemiological studies in remote areas where laboratories are not readily accessible for conventional assays.
Subject(s)
Antigens, Protozoan/immunology , Dog Diseases/diagnosis , Epitopes, B-Lymphocyte/immunology , Leishmania/physiology , Leishmaniasis, Visceral/diagnosis , Recombinant Proteins/immunology , Zoonoses/diagnosis , Adult , Aged , Animals , Antibodies, Protozoan/blood , Antigens, Protozoan/genetics , Cross Reactions , Dogs , Epitopes, B-Lymphocyte/genetics , Female , Humans , Male , Middle Aged , Recombinant Proteins/genetics , Sensitivity and Specificity , Serologic Tests , Young AdultABSTRACT
The present study evaluated the cytokine profile in PBMC supernatants and the humoral response in mucosal leishmaniasis (ML) patients and in healthy subjects living in an endemic area. Four proteins, which had previously proven to be antigenic in the human disease, were tested: LiHyM, enolase, eukaryotic initiation factor 5a, and Beta-tubulin. Results showed that all of the proteins stimulated human cells with higher IFN-γ and lower IL-4 and IL-10 levels. The analysis of antibody isotypes correlated with cell response, since the IgG2 production was higher than IgG1 in both groups. By contrast, a Th2 response was found when an antigenic Leishmania extract was used. Serological analyses revealed high sensitivity and specificity values for the serodiagnosis of the disease, when compared to the data obtained using the antigenic preparation. In conclusion, this study presents new candidates to be evaluated as biomarkers in tegumentary leishmaniasis.
Subject(s)
Antibody Formation/immunology , Antigens, Protozoan/immunology , Leishmania/immunology , Leishmaniasis, Cutaneous/immunology , Protozoan Proteins/immunology , Recombinant Proteins/immunology , Adult , Eukaryotic Initiation Factor-5/immunology , Female , Humans , Immunoglobulin G/immunology , Interferon-gamma/immunology , Interleukin-10/immunology , Interleukin-4/immunology , Leukocytes, Mononuclear/immunology , Male , Middle Aged , Th2 Cells/immunology , Tubulin/immunology , Young AdultABSTRACT
In the present study, a conserved Leishmania hypothetical protein, LiHyE, was evaluated for the serodiagnosis of leishmaniasis. Results showed that it presented high sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) to serologically identify visceral leishmaniasis (VL) dogs when 40 positive sera and 95 cross-reactive samples were used. rLiHyE also showed the best results of sensitivity, specificity, PPV, and NPV to identify tegumentary leishmaniasis (TL) and VL patients when 45 leishmaniasis patients' sera and 90 cross-reactive samples were used. Results were better in comparison to those obtained when rA2 or Leishmania antigenic extract was employed as controls. The posttreatment follow-up showed that rLiHyE-specific antibodies declined significantly after the end of treatments, and a predominance of the IgG2 subclass was found in comparison to IgG1 levels in both TL and VL patients. In conclusion, rLiHyE can be considered a candidate for the serodiagnosis of canine and human leishmaniasis.
Subject(s)
Biomarkers/blood , Dog Diseases/diagnosis , Leishmaniasis, Visceral/diagnosis , Leishmaniasis/diagnosis , Protozoan Proteins , Serologic Tests , Animals , Antibodies, Protozoan , Antigens, Protozoan , Dog Diseases/drug therapy , Dog Diseases/parasitology , Dogs , Enzyme-Linked Immunosorbent Assay/methods , Follow-Up Studies , Humans , Immunoglobulin G/blood , Immunoglobulin G/immunology , Leishmaniasis/drug therapy , Leishmaniasis/parasitology , Leishmaniasis, Visceral/drug therapy , Leishmaniasis, Visceral/parasitology , Protozoan Proteins/immunology , Recombinant Proteins/immunology , Sensitivity and Specificity , Serologic Tests/methodsABSTRACT
New candidates for serological markers against leishmaniasis are required to be identified, since the presence of high titers of anti-Leishmania antibodies remain detected in sera of treated and cured patients, when current antigens have being employed. In this study, the diagnostic performance of a conserved Leishmania hypothetical protein was evaluated against a human and canine serological panel. The serological follow-up of the patients was also evaluated, using this recombinant antigen (rLiHyS) in ELISA assays. In the results, high sensitivity and specificity values were found when rLiHyS was used in the serological tests, while when the recombinant A2 (rA2) protein or an antigenic Leishmania preparation were used as controls, low sensitivity and specificity were found. Regarding the serological follow-up of the patients, significant reductions in the anti-rLiHyS antibody levels were found and, one year after the treatments, the anti-protein IgG production was similar to this found in the non-infected groups, reflecting a drop of the anti-rLiHyS antibody production. In conclusion, the present study shows for the first time a new recombinant antigen used to identify tegumentary and visceral leishmaniasis, as well as being able to serologically distinguish treated and cured patients from those developing active disease.
Subject(s)
Leishmania braziliensis/immunology , Leishmania infantum/immunology , Leishmaniasis, Cutaneous/diagnosis , Leishmaniasis, Visceral/diagnosis , Protozoan Proteins/immunology , Adult , Amino Acid Sequence , Animals , Antigens, Helminth/genetics , Antigens, Helminth/immunology , Biomarkers/blood , Chagas Disease/diagnosis , Chagas Disease/immunology , Dog Diseases/blood , Dog Diseases/immunology , Dog Diseases/parasitology , Dogs , Enzyme-Linked Immunosorbent Assay , Female , Humans , Leishmania braziliensis/chemistry , Leishmania infantum/chemistry , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Visceral/diet therapy , Leishmaniasis, Visceral/immunology , Male , Middle Aged , Prognosis , Protozoan Proteins/genetics , Recombinant Proteins/immunology , Sensitivity and Specificity , Serologic Tests/methods , Young AdultABSTRACT
In a proteomics approach conducted with Leishmania amazonensis, parasite proteins showed either an increase or a decrease in their expression content during extensive in vitro cultivation, and were related to the survival and the infectivity of the parasites, respectively. In the current study, a computational screening was performed to predict virulence factors among these molecules. Three proteins were selected, one of which presented no homology to human proteins. This candidate, namely small myristoylated protein-3 (SMP-3), was cloned, and its recombinant version (rSMP-3) was used to stimulate peripheral blood mononuclear cells (PBMCs) from healthy subjects living in an endemic area of leishmaniasis and from visceral leishmaniasis patients. Results showed high interferon-γ (IFN-γ) production and low levels of interleukin 10 (IL-10) in the cell supernatants. An in vivo experiment was then conducted on BALB/c mice, which were immunized with rSMP-3/saponin and later challenged with Leishmania infantum promastigotes. The rSMP-3/saponin combination induced high production of protein-specific IFN-γ, IL-12, and granulocyte-macrophage colony-stimulating factor (GM-CSF) by the spleen cells of the immunized mice. This pattern was associated with protection, which was characterized by a significant reduction in the parasite load in distinct organs of the animals. Altogether, these results have revealed that this new virulence factor is immunogenic in both mice and humans, and have proven its protective efficacy against visceral leishmaniasis in a murine model.
Subject(s)
Antigens, Protozoan/metabolism , Leishmania/pathogenicity , Leishmaniasis, Visceral/prevention & control , Leishmaniasis, Visceral/parasitology , Protozoan Proteins/metabolism , Virulence Factors/metabolism , Amino Acid Sequence , Animals , Antigens, Protozoan/chemistry , Computational Biology , Cytokines/metabolism , Epitopes, T-Lymphocyte/metabolism , Humans , Immunity, Cellular , Immunity, Humoral , Leishmania infantum , Leishmaniasis, Visceral/immunology , Leukocytes, Mononuclear/metabolism , Linear Models , Mice, Inbred BALB C , Molecular Sequence Annotation , Protozoan Proteins/chemistry , Reproducibility of Results , Structural Homology, ProteinABSTRACT
Visceral leishmaniasis (VL) is a potentially fatal disease, in which the treatment based on chemotherapy is considered toxic. The cure of disease is associated with the life-long Th1-type immunity against the infection. The Th1-related cytokines production by peripheral blood mononuclear cells (PBMCs) seems to be crucial for host control of parasite load and clinical cure. In the current study, we used five proteins (IgE-dependent histamine-releasing factor [HRF], LiHyD, LiHyV, LiHyT and LiHyp6) recently shown to be antigenic and/or immunogenic in the canine VL, aiming to evaluate the antigen-specific antibody levels and cytokine production in PBMCs culture supernatants collected from VL patients before and after anti-VL treatment. In the results, when PBMCs were exposed to rHRF, rLiHyD and rLiHyT, higher IFN-γ and lower IL-10 levels were observed in all patients that were treated and clinically cured. Analysis of specific antibody subclasses was in line with in vitro cellular response, since a higher IgG2 production was found in the treated and cured patients, when compared to the IgG1 subclass levels. In addition, evaluating the diagnostic efficacy of the recombinant molecules, the rHRF, rLiHyD and rLiHyT proteins showed the best results in the serology assays to identify all VL patients, as well as these antigens were not recognized by antibodies in sera from non-infected subjects or those with leishmaniasis-related diseases. Our results corroborate the view that clinical cure of VL is associated with a sustained Th1-related response, and indicate the potential use of rHRF, rLiHyD and rLiHyT as immune biomarkers of VL treatment.
Subject(s)
Antibodies, Protozoan/blood , Biomarkers, Pharmacological/blood , Leishmania infantum/physiology , Leishmaniasis, Visceral/diagnosis , Leukocytes, Mononuclear/immunology , Th1 Cells/immunology , Adult , Animals , Antigens, Protozoan/genetics , Antigens, Protozoan/immunology , Cells, Cultured , Disease Progression , Dogs , Female , Humans , Interferon-gamma/metabolism , Interleukin-10/metabolism , Leishmaniasis, Visceral/therapy , Leukocytes, Mononuclear/parasitology , Lymphocyte Activation , Male , Middle Aged , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Young AdultABSTRACT
Visceral leishmaniasis (VL) represents a serious public health problem, as Leishmania infantum is one of main disease causative agents in the Americas. In a previous immunoproteomic study, the prohibitin (PHB) protein was identified in L. infantum promastigote and amastigote extracts by antibodies in asymptomatic and symptomatic VL dog sera. This protein was found to be highly conserved between different Leishmania spp., but it presented a low identity with amino acid sequences of other organisms. The aim of the present study was to evaluate the cellular response induced by the recombinant PHB (rPHB) protein in BALB/c mice, as well as in PBMCs purified from untreated and treated VL patients, as well as to evaluate its protective efficacy against an infection by L. infantum promastigotes. Our data showed that there was a Th1 cellular response to rPHB, based on high levels of IFN-γ, IL-12, and GM-CSF in the immunized animals, as well as a proliferative response specific to the protein and higher IFN-γ levels induced in PBMCs from individuals who had recovered from the disease. The protection was represented by significant reductions in the parasite load in the animals' spleen, liver, bone marrow, and draining lymph nodes, as compared to results found in the control groups. In addition, an anti-rPHB serology, using a canine and human serological panel, showed a high performance of this protein when diagnosing VL based on high sensitivity and specificity values, as compared to results found for the rA2 antigen and the soluble Leishmania antigenic extract. Our data suggest that PHB has a potential application for the diagnosis of canine and human VL through antibody detection, as well as an application as a vaccine candidate to protect against disease.
Subject(s)
Leishmaniasis, Visceral/diagnosis , Leishmaniasis, Visceral/immunology , Repressor Proteins/immunology , Animals , Antigens, Protozoan/immunology , Dogs , Humans , Leishmania infantum/immunology , Leishmania infantum/metabolism , Leishmaniasis, Visceral/metabolism , Mice , Mice, Inbred BALB C , Prohibitins , Recombinant Proteins/metabolism , Repressor Proteins/metabolism , Th1 Cells/immunology , Vaccines/metabolismABSTRACT
Different Leishmania proteins have been evaluated in order to find a potential vaccine candidate or diagnostic marker capable of providing long lasting protection against infection or helping to identify infected mammalian hosts, respectively. However, just few molecules have fulfilled all the requirements to be evaluated. In the current study, we evaluated the prophylactic and diagnostic value against visceral leishmaniasis (VL) of a small glutamine-rich tetratricopeptide repeat-containing (SGT) protein from Leishmania infantum species. In a first step, the immune response elicited by the immunization using the recombinant protein (rSGT) plus saponin was evaluated in BALB/c mice. Immunized animals had a low parasitism in all evaluated organs. They developed a specific Th1 immune response, which was based on protein-specific production of IFN-γ, IL-12 and GM-CSF, and a humoral response dominated by antibodies of the IgG2a isotype. Both CD4+ and CD8+ T cells contributed to the IFN-γ production, showing that both T cell subtypes contribute to the resistance against infection. Regarding its value as a diagnostic marker, rSGT showed maximum sensitivity and specificity to serologically identify L. infantum-infected dog and human sera. No cross-reactivity with sera from humans or dogs that had other diseases was found. Although further studies are necessary to validate these findings, data showed here suggest immunogenicity of rSGT and its protective effect against murine VL, as well as its potential for the serodiagnosis of human and canine VL.
Subject(s)
Leishmania infantum/immunology , Leishmaniasis Vaccines/immunology , Leishmaniasis, Visceral/diagnosis , Leishmaniasis, Visceral/prevention & control , Protozoan Proteins/immunology , Animals , Antibodies, Protozoan/immunology , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/pathology , Cross Reactions , Cytokines/immunology , Dogs , Female , Humans , Immunoglobulin G/immunology , Leishmania infantum/genetics , Leishmaniasis Vaccines/genetics , Leishmaniasis, Visceral/genetics , Leishmaniasis, Visceral/immunology , Mice, Inbred BALB C , Protozoan Proteins/genetics , Protozoan Proteins/pharmacology , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Recombinant Proteins/pharmacology , Th1 Cells/immunology , Th1 Cells/pathologyABSTRACT
In the Americas, Brazil is responsible by 90% of the cases registered of visceral leishmaniasis (VL), and Leishmania infantum is the most common parasite species responsible by disease in Brazilian dogs and humans. A precise diagnosis may allow to a faster and more effective treatment against the disease, which increases the possibility of cure, as well as to induce less toxic effects, due to a lower time exposition for the chemotherapeutics. In a previous study, two L. infantum mimotopes, B10 and C01 clones, were recognized by antibodies in VL dogs sera by a phage display technology, and were well-successfully evaluated as vaccine candidates against visceral and tegumentary leishmaniasis. In the present work, the diagnostic efficacy of these clones, as well as of their exogenous peptides (B10: LSFPFPG and C01: FTSFSPY), was evaluated to diagnose canine and human VL. ELISA assays were performed with the four antigens, and results showed that both clones, as well as their synthetic peptides; showed high sensitivity and specificity values to identify VL samples, presenting an excellent performance to serologically diagnose VL-developing humans and dogs. On the other hand, a wild-type phage, a random non-specific clone and a L. infantum antigenic preparation were used as controls, and showed worst sensitivity and specificity results. In conclusion, besides their biological action as vaccine, B10 and C01 phages and their synthetic peptides could be considered as new markers for the serodiagnosis of canine and human VL.
Subject(s)
Antigens, Protozoan/immunology , Cell Surface Display Techniques/methods , Leishmaniasis, Visceral/diagnosis , Leishmaniasis, Visceral/veterinary , Peptides/immunology , Protozoan Proteins/immunology , Serologic Tests/methods , Animals , Antibodies, Protozoan/immunology , Bacteriophages , Biomarkers/blood , Brazil , Dog Diseases/diagnosis , Dogs , Enzyme-Linked Immunosorbent Assay/methods , Female , Humans , Leishmania infantum/immunology , Male , Peptides/isolation & purification , Sensitivity and SpecificityABSTRACT
In the present study, a conserved Leishmania hypothetical protein, namely LiHypA, was evaluated for the serodiagnosis of visceral and tegumentary leishmaniasis in dogs and humans. This protein showed a high amino acid sequence homology between viscerotropic and cutaneotropic Leishmania species. An enzyme-linked immunosorbent assay (ELISA) was developed using the recombinant antigen (rLiHypA), in addition to the A2 protein and two parasite antigenic preparations, which were used as controls. Regarding human diagnosis, results showed that rLiHypA was more sensitive and specific than ELISA-L. braziliensis SLA in detecting both cutaneous or mucosal leishmaniasis patients, but not those from Chagas disease patients or healthy subjects. Regarding canine diagnosis, this recombinant antigen showed higher sensitivity and specificity values, as well as a perfect accuracy to identify asymptomatic and symptomatic visceral leishmaniasis (VL) in dogs, but not those from vaccinated animals or those developing babesiosis, ehrlichiosis, or Chagas disease. However, using the rA2 protein or L. braziliensis SLA as controls, significant cross-reactivity was found when these samples were used, hampering their sensitivity and specificity values for the diagnosis. In this context, LiHypA could be considered a candidate to be evaluated for the serodiagnosis of visceral and tegumentary leishmaniasis in dogs and humans.
Subject(s)
Antigens, Protozoan/metabolism , Chagas Disease/diagnosis , Enzyme-Linked Immunosorbent Assay/methods , Leishmania/immunology , Leishmaniasis, Cutaneous/diagnosis , Leishmaniasis, Visceral/diagnosis , Recombinant Proteins/metabolism , Animals , Antigens, Protozoan/genetics , Antigens, Protozoan/immunology , Chagas Disease/immunology , Conserved Sequence/genetics , Cross Reactions , Dogs , Humans , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Visceral/immunology , Predictive Value of Tests , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
In the present study, the Leishmania braziliensis enolase protein was evaluated as a vaccine candidate against visceral leishmaniasis (VL). The DNA sequence was cloned and the recombinant protein (rEnolase) was evaluated as a vaccine, associated with saponin, as an immune adjuvant. The protective efficacy of the rEnolase plus saponin combination was investigated in BALB/c mice against Leishmania infantum infection. The results revealed that the vaccine induced higher levels of IFN-γ, IL-12, and GM-CSF when a capture ELISA and flow cytometry were performed, as well as an antileishmanial nitrite production after using in vitro stimulation with rEnolase and an antigenic Leishmania preparation. The vaccinated animals, when compared to the control groups, showed a lower parasite burden in the liver, spleen, bone marrow, and paws' draining lymph nodes when both a limiting dilution technique and RT-PCR assay were performed. In addition, these mice showed low levels of antileishmanial IL-4, IL-10, and anti-Leishmania IgG1 isotype antibodies. Partial protection was associated with IFN-γ production, which was mainly mediated by CD4+ T cells. In conclusion, the present study's data showed that the L. braziliensis enolase protein could be considered a vaccine candidate that offers heterologous protection against VL.
Subject(s)
Leishmania braziliensis/enzymology , Leishmaniasis Vaccines/immunology , Leishmaniasis, Visceral/prevention & control , Phosphopyruvate Hydratase/immunology , Adjuvants, Immunologic , Animals , Enzyme-Linked Immunosorbent Assay , Female , Gene Expression Regulation, Enzymologic , Granulocyte-Macrophage Colony-Stimulating Factor/genetics , Granulocyte-Macrophage Colony-Stimulating Factor/metabolism , Interferon-gamma/genetics , Interferon-gamma/metabolism , Interleukin-12 , Leishmania braziliensis/immunology , Leishmania infantum/immunology , Mice , Mice, Inbred BALB C , Phosphopyruvate Hydratase/metabolism , Recombinant Proteins/immunology , T-Lymphocytes/immunologyABSTRACT
Serological methods used to diagnose visceral leishmaniasis (VL) are considered minimally invasive, but they present problems related with their sensitivity and/or specificity. In this study, a subtractive selection using the phage display technology against antibodies from healthy subjects living in endemic and non-endemic areas of disease, as well as from Chagas disease patients and those developing active VL, was developed. The aim of this study was to select bacteriophage-fused epitopes to be used in the serodiagnosis of human VL. Eight phage clones were selected after the bio-panning rounds, and their reactivity was evaluated in a phage-ELISA assay against a human serological panel. A wild-type clone and the recombinant K39-based immunochromatographic test were used as controls. In the results, it was shown that all clones showed an excellent performance to serologically identify VL patients, demonstrating the feasibility of the isolated phages for developing a specific and sensitive serodiagnosis of human VL.
Subject(s)
Antigens, Protozoan/immunology , Cell Surface Display Techniques/methods , Enzyme-Linked Immunosorbent Assay/methods , Leishmania infantum/immunology , Leishmaniasis, Visceral/diagnosis , Protozoan Proteins/immunology , Adult , Antibodies, Protozoan/immunology , Chagas Disease/immunology , Epitopes/immunology , Female , Humans , Male , Middle Aged , Sensitivity and Specificity , Serologic Tests/methods , Young AdultABSTRACT
Human tegumentary leishmaniasis (HTL), characterized by skin ulcers that may spread and cause dreadful and massive tissue destruction of the nose and mouth, is considered a neglected tropical disease, and it is a serious threat to global health due to its continuous expansion, favored by the lifecycle of its causative organism that is maintained in domestic animal reservoirs and anthropophilic sand fly species. Serodiagnosis of HTL is a great challenge due to many biological factors, including hampered specificity and/or sensitivity. This investigation addresses the unmet need for new diagnostic markers of HTL, and describes a simple platform to improve the serodiagnosis. A constrained conformational phage display random peptide library combined with a magnetic microsphere-based subtraction strategy was used to identify ligands with potential diagnostic applications. Six clones were selected against IgG antibodies from HTL patients, characterized by sequencing and confirmed by a phage-ELISA using sera from patients developing visceral leishmaniasis (n=20), Chagas disease (n=10), mucosal (n=30) and cutaneous (n=20) leishmaniasis; as well as from healthy subjects living in endemic (n=20) and non-endemic (n=30) areas of leishmaniasis. A wild-type M13-phage clone and a soluble Leishmania antigenic extract were used as negative and positive controls, respectively. Three clones reached 100% sensitivity and specificity, without any cross-reactivity with sera from patients with leishmaniasis-related diseases. Briefly, we describe for the first time a set of serological markers based on three immunodominant mimotopes that showed 100% accuracy, and that could be used in a phage-ELISA assay for the HTL serodiagnosis.